Lymphoma

Janssen and Pharmacyclics intend to voluntarily withdraw the U.S. indications of ibrutinib for certain patients with lymphoma, according to a press release.

The FDA approved leniolisib as the first treatment for activated phosphoinositide 3-kinase delta syndrome in adults and pediatric patients 12 years of age and older.

Axicabtagene ciloleucel significantly extended survival compared with historic standard of care in a curative setting for adults with previously untreated relapsed or refractory large B-cell lymphoma, according to the agent’s manufacturer.

The FDA is aware of 19 cases of squamous cell carcinoma in scar tissue that forms around breast implants, the agency announced today in a safety communication.

A novel chimeric antigen receptor T-cell therapy induced response among adults with advanced large B-cell lymphoma who relapsed after previous CAR-T, study results showed.

Patients who received chimeric antigen receptor T cells for relapsed or refractory diffuse large B-cell lymphoma feared disease progression less than those who received standard regimens, results of a cross-sectional study showed.

Women with diffuse large B-cell lymphoma experienced significantly longer PFS and OS when receiving chemotherapy in the afternoon compared with the morning, according to data published in JCI Insight.

A phase 1/phase 2 trial of lisocabtagene maraleucel for adults with advanced chronic lymphocytic leukemia or small lymphocytic lymphoma met its primary endpoint, according to the agent’s manufacturer.

NEW ORLEANS — Patients older than 80 years of age with diffuse large B-cell lymphoma more than tripled their overall survival when receiving at least six cycles of chemotherapy.